CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
News|Articles|January 2, 2004
- Pharmaceutical Technology-01-02-2004
- Volume 28
- Issue 1
New Supply-Chain Dynamics
Author(s)Jim Miller
As manufacturers move to manufacture to demand rather than to forecast, the traditional wholesaling business model is being transformed.
Advertisement
Articles in this issue
almost 23 years ago
Coprocessed Excipients for Solid Dosage Formsalmost 23 years ago
Manufacturing Execution Systemsalmost 23 years ago
State-of-the-Art Packaging Machinesalmost 23 years ago
January 2004almost 23 years ago
Medicare Bill Contains Significant Changes for Drug Manufacturersalmost 23 years ago
The Bioterrorism Actalmost 23 years ago
In the Spotlight--February 2004almost 23 years ago
January 2004Advertisement
Related to this article
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Improving Oral Peptide Delivery Through Structural Modifications
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
Drapeau’s AI Deep Dive: The Price of Acceptance in Regulated AI
4
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
5